Medical College of Wisconsin
CTSIResearch InformaticsREDCap

The use of inhaled nitric oxide in a wide variety of clinical problems. Pediatr Clin North Am 1998 Jun;45(3):531-48

Date

07/08/1998

Pubmed ID

9653435

DOI

10.1016/s0031-3955(05)70026-2

Scopus ID

2-s2.0-0031866978 (requires institutional sign-in at Scopus site)   36 Citations

Abstract

Inhaled nitric oxide (NO) clearly decreased pulmonary vascular resistance in pediatric patients with pulmonary hypertension, regardless of the underlying origin of the pulmonary hypertension. In persistent pulmonary hypertension of the neonate (PPHN) and CHD, the use of inhaled NO appears to improve the outcome of these patients. In acute respiratory distress syndrome (ARDS) and surfactant deficiency the role of inhaled NO therapy remains unclear. The use of inhaled NO is safe in a carefully monitored setting with a delivery system designed to minimize the generation of NO2.

Author List

Nelin LD, Hoffman GM

Author

George M. Hoffman MD Chief, Professor in the Anesthesiology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Administration, Inhalation
Drug Monitoring
Heart Defects, Congenital
Humans
Hyaline Membrane Disease
Infant, Newborn
Nitric Oxide
Persistent Fetal Circulation Syndrome
Respiratory Distress Syndrome, Newborn
Treatment Outcome